Global commercial-stage diagnostics firm Oxford Immunotec has started enrolling patients in the PROTECT clinical trial, which is designed to show the clinical value of its T-SPOT.CMV and T-SPOT.PRT products.
The T-SPOT.CMV test is designed to measure the strength of T cell responses to cytomegalovirus (CMV) as a measure of susceptibility to CMV infection.
CMV is a common and serious complication in both solid organ and stem cell transplantation, and the T-SPOT.CMV test is claimed to have the potential to assist clinicians with monitoring antiviral prophylaxis and evaluating patients at risk from this disease.
The company's T-SPOT.PRT (Panel of Reactive T cells) test measures a patient's T cell immune response to foreign tissue to assist in the evaluation of risk of graft rejection.
Graft rejection is generally caused by immune responses to the transplanted organ, and both antibody and T cell responses are responsible for rejection events.
Designed to complement commonly used antibody tests, the T-SPOT.PRT test provides additional information on the T cell side of the immune system for which currently there are no good measurement tools.
Oxford Immunotec CEO Dr Peter Wrighton-Smith said: "We are pleased to announce that we have begun the enrollment process for our PROTECT study.
"We are excited about the potential application of our T-SPOT.CMV and T-SPOT.PRT products in transplant medicine and the clinical and economic value they could bring to this setting."
Oxford Immunotec is focused on developing and commercialising proprietary tests for management of immune-regulated conditions.